Using a novel approach that detects changes in the conformation of ERα, we studied the efficacy of anti-estrogens to inactivate ERα under different experimental conditions. We show that phosphorylation of serine-305 in the hinge region of ERα by protein kinase A (PKA) induced resistance to tamoxifen. Tamoxifen bound but then failed to induce the inactive conformation, invoking ERα-dependent transactivation instead. PKA activity thus induces a switch from antagonistic to agonistic effects of tamoxifen on ERα. In clinical samples, we found that downregulation of a negative regulator of PKA, PKA-RIα, was associated with tamoxifen resistance prior to treatment. Activation of PKA by downregulation of PKA-RIα converts tamoxifen from an ERα inhibitor into a growth stimulator, without any effect on ICI 182,780 (Fulvestrant).
Introduction
Approximately 70% of all breast cancers are dependent for their growth on estrogen and on a functional estrogen receptor α (ERα). Hence, ER-positive breast cancer is usually treated with hormone reduction or anti-estrogens (1) . The most commonly used anti-estrogen is tamoxifen, and it has been calculated that about one million years of life are saved by tamoxifen per year in the developed countries (2) . Still, only half of the recurrences in ER+ breast tumors respond to tamoxifen, while the other half show resistance. Mutations in ER that lead to resistance are rarely found in patients (3) , whereas multiple other mechanisms have been associated with tamoxifen resistance in vitro. Reported are: phosphorylation of the ERα by protein kinase A (PKA) (4) or MAP-kinase (5), overexpression of c-erbB2 (6), EGF-R or SRC-1 (7) , and stabilization of the interaction between ERα and SRC-1 by cyclin D1 (8) and cyclin A-CDK2 (9) . Whether these mechanisms are operational in tamoxifen-resistant breast cancer is unclear. Understanding the mechanism of tamoxifen resistance in ER+ breast cancers should allow early identification of these tumors and adaptation of the treatment before more aggressive cells arise.
ERα is a member of the nuclear hormone receptor superfamily and regulates transcription of ERspecific target genes in response to the hormone estradiol (E2) (10) . ERα contains several functional domains, including a centrally located DNA binding domain connected through a hinge region to a C-terminal ligand binding domain (LBD) that binds the agonist estradiol, but also antagonists such as tamoxifen and ICI-182,780 (commercial name: Faslodex or Fulvestrant). Hormone binding results in rapid dissociation from chaperone proteins, leading to binding of an ER homodimer to its cognate estrogen responsive element (ERE) binding site on the DNA. This initiates transcription by recruiting the basal transcription machinery through a variety of coactivators, including steroid receptor cofactor-1 (SRC-1) and AIBI (11) . It is this recruitment that is inhibited by anti-estrogens.
The conformation of the LBD of ER is affected by ligand binding (12) (13) (14) (15) . Estradiol binding affects the conformation of helix12 of the LBD such that coactivators are recruited and transcription ensues. Anti-estrogens like tamoxifen and ICI-182,780 bind to the same site (16) , but induce a reorientation of this particular helix, thereby preventing the interaction with coactivators and inhibiting ER-driven transcription. Yet, the effects of the individual anti-estrogens are not identical (17) (18) (19) . For example, a fraction of ER-positive tamoxifen resistant breast tumors is still sensitive to ICI-182,780 in vitro as well as in vivo in patients (17, (20) (21) (22) . The fact that estrogen and antiestrogens induce different ER conformations was the rationale behind designing a fluorescence resonance energy transfer (FRET) probe that can monitor these conformations in living cells (23) .
Experimental Procedures
Cell culture, transfection, and ERE-luciferase reporter assays U2OS and T47D cells were cultured in DMEM medium in the presence of 10% FCS and standard antibiotics. U2OS cells containing ER constructs were cultured in phenol redfree DMEM medium containing 5% charcoal treated serum (CTS, Hyclone). For the FRET experiments, cells were cultured on 2 cm round glass coverslips, and at the times indicated estradiol (Sigma), 4-OH-tamoxifen (Sigma), or ICI-182,780 (Tocris) was added at the concentrations indicated. Forskolin (Sigma) was added 15 min prior to measurements at a final concentration of 10 −5 M. For the ERE-luciferase experiments, 10 −7 M estrogen or anti-estrogen was added to the medium after transfection, followed by culturing the cells for 48 hr before harvesting. For transient transfections, 4 × 10 5 U2OS cells were plated in a 6-well plate culture dish and cultured overnight. The cells were transfected with 1 µg of expression vectors pCMV-cyclin D1, pCMV-SRC-1 (24), and 0.4 µg of pcDNA3-YFP-ER-CFP (see below) using Transfast reagents (Promega) following the manufacturer's protocol. For ERE-luciferase reporter assays, cells were transfected with 1 µg ERE-Tk-Firefly luciferase (25) and 1 ng of SV40 Renilla luciferase construct, and cells were incubated under the conditions indicated for 48 hr. The luciferase assay was performed as described (25) .
Fluorescence resonance energy transfer (FRET)
For FRET experiments, cells on coverslips were placed on an inverted Zeiss Axiovert 135 microscope equipped with a dry Achroplan 63x objective. FRET equipment was as described previously (26) . CFP was excited at 432 ± 5 nm and emission of YFP was detected at 527 nm and CFP at 478 nm. FRET was expressed as ratio of YFP to CFP signals. The ratio was arbitrarily set as 1.0 at the onset of the experiment. Changes are expressed as percent deviation from this initial value of 1.0. For data acquisition, Felix software (PTI Inc.) was used.
YFP-ER-CFP constructs and in vitro phosphorylation
The pCMV-ERα construct was obtained from P. Chambon (Strasbourg). A fusion construct was made by ligation of PCR products from ERα and CFP in-frame in the YFP-PH pcD-NA3 vector (26) . We used primer 5ʹCCCAGAATCAATGAC CCTCCACACCAAAGCATCT, creating an EcoRI site, and 5ʹCCCACTCGAGGAC TGTGGCAGGGAAACCCTCT, eliminating the stop codon of ERα, and introduced a XhoI site compatible with the 5ʹ SalI site from CFP (sequence 5ʹCCCA GTCGACATGGTGAGCAAGGGCGAGGA), while a stop
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codon was introduced at the 3ʹ end (5ʹCCCATCTAGATC ACTTGTACAGCTCGTCCATG). The single fluorescent protein containing ERα constructs (YFP-ERα and ERα-CFP) was constructed in an identical manner. Site-directed mutagenesis of serine-236 and -305 to alanine was performed with the YFP-ERα-CFP construct as a template using the appropriate modified oligonucleotides. All constructs were verified by sequence analysis using 4Peaks (mekentosj.com). The pcDNA3-YFP-ERα-CFP construct was transfected in U2OS cells, and after 48 hr, cells were inspected by confocal microscopy for YFP emission at 500-565 nm. Protein expression was examined by Western blotting using antibodies against ER-α (Stressgen Biotechnologies Corp) and GFP (27) and detected using an ECL detection kit (Amersham).
The in vitro protein kinase A assay was performed as described before (28 
Microarray analysis
Patients were participating in the tamoxifen trial (MTAMOX) of the Comprehensive Cancer Center Amsterdam, where no tamoxifen versus one year and three years adjuvant tamoxifen treatment were compared with respect to recurrence-free interval and overall survival in postmenopausal women with stage I-IIIB invasive breast cancer (13) . All tumors were ERpositive by immunohistochemical staining. There were two randomizations: first, between no tamoxifen and tamoxifen, and after one year in the tamoxifen arm, between 1 and 3 years tamoxifen. In this study, only patients in the initial tamoxifen arm were included.
Starting date was date of first randomization, ranging from 10/86 to 11/93. Median follow-up was 132 months for the 50 patients without recurrence against 41 months (7-132) for the 20 patients who recurred. As estimated by the inverse survival technique (inverting the role of recurrence/ death and censoring in calculating the Kaplan-Meier curve), all patients had a potential follow-up of at least 5 years, 45% a follow-up of at least 9 years, and 25% a follow-up of at least 10 years. Follow-up was closed November 2002.
RNA extraction, amplification, and hybridization
Tumor biopsies were frozen in liquid nitrogen at the time of surgery and stored at −80°C. 30 cryostat sections of 30 µm were cut from the tumor tissue. RNA was isolated from these sections using RNAzol and a polytron homogenizer according to manufacturer's protocol (Campro Scientific, Veenendaal, The Netherlands), followed by DNase treatment. 4 µg of this total RNA was amplified, using a modified Eberwine amplification protocol (http://microarrays.nki. nl) yielding an average of 40 µg antisense RNA (aRNA).
All labeling and hybridization protocols are published at http://microarrays.nki.nl/download/protocols. 10 µg aRNA from 56 tumors (16 recurrence, 40 nonrecurrence) of this series was pooled to create a reference. 2 µg aRNA of each tumor was primed with random hexamers and labeled with Cy3 or Cy5 in a cDNA reaction, and hybridized on a NKI 18K human cDNA array (http://microarrays.nki.nl) against the reference, labeled with the other Cy dye. All hybridizations were done twice; in the second hybridization, the labels were switched (color reverse). Arrays were scanned with a confocal laser scanner (Scanarray 4000 GSI Lumonics).
Array data analysis
Fluorescent intensities from the arrays were quantified with Imagene software (Biodiscovery). After normalization of the Cy3/Cy5 signal (30) , an average ratio of the two-color reverse hybridizations for each gene was calculated. Genes were selected that were significantly deregulated in minimally 5 tumors (that is, at least a 2-fold difference and p value < 0.01) (31) . For these 6,000 genes, the correlation between the prognostic category (recurrence versus nonrecurrence) and the logarithmic expression ratios for all 70 samples was calculated, and a rank order was made using the Wilcoxon 164 rank sum test, based on the magnitude of the correlation coefficient (32) . After Monte Carlo analysis, a cutoff point of a correlation of 0.37 was chosen. Some 100 genes appeared to have a higher correlation and were thus strongly associated with recurrence. PKA-RIα was one of these genes with a high correlation (rank order 53), and was shown by a twosample t test to be significantly downregulated in the group with recurrence compared to the group without recurrences (two-sample t test for combined probes; p value = 0.0000697).
The other genes of the PKA pathway included in the array did not show a significant difference between the recurrence and nonrecurrence group (p value > 0.05). All data for the relevant probes is shown in Supplemental Table S2 .
Results

FRET marks inactivation of ERα
We generated a recombinant ERα with two variants of the green fluorescent protein: YFP at the N-and CFP at the C terminus ( Figure 1A ). Any alteration in position or orientation of the CFP and YFP molecules may result in a change in energy transfer between these fluorophores (23, 26) . First, we determined whether the YFP/CFP modification affects the normal behavior of ERα. U2OS cells stably transfected with the YFP-ER-CFP construct showed fluorescent nuclei ( Figure 1B ) containing a 119 kDa YFP-ER-CFP fusion protein, as detected by Western blot analysis with anti-ER and anti-GFP antibodies ( Figure 1C ). This construct was normally able to induce ERE-mediated transactivation. Culturing the cells with estradiol for 48 hr resulted in a 35-fold increase of ERE-luciferase activity over control cells grown in estrogen-depleted serum (CTS), whereas tamoxifen or ICI-182,780 hardly induced ERE-mediated reporter activity ( Figure 1D) . These values were comparable to those found using a nonmodified pCMV-ER construct (data not shown), indicating that the GFP modifications did not alter the activity of ER. Moreover, the pCMV-ER wt and the YFP-ER-CFP fusion construct showed comparable IC 50 and EC 50 values for estradiol, OH-tamoxifen, and ICI-182,780 in transactivation assays (Figures 1E-1G ).
Subsequently, we measured conformational changes in ERα by FRET after addition of estradiol (E2) or the anti-estrogens tamoxifen and ICI-182,780. Alterations in the distance or orientation of CFP and YFP will potentially affect energy transfer from CFP to YFP, which can be observed when CFP is excited at 432 nm and the emission of CFP (at 478 nm) and YFP (at 527 nm) is simultaneously measured (Figure 2A) . In case of energy transfer, emission of YFP should occur at the expense of CFP (23) , and alterations in FRET (fluorescence resonance energy transfer) are depicted as changes in ratio between these two signals. Living U2OS cells transfected with the YFP-ER-CFP construct were assayed in the presence of various combinations of estrogen (E2), tamoxifen, and ICI-182,780 (as indicated in Figures 2B-2D ). An alteration in FRET was observed only after addition of tamoxifen or ICI-182,780, and reached completion within 10 min. E2 did not affect FRET, not even when a 10-fold molar excess was added after anti-estrogen addition ( Figure 2C) . Apparently, the YFP-ER-CFP FRET probe only detected ER inactivation by the anti-estrogens tamoxifen or ICI-182,780, and not activation by E2. Application of the FRET in physiologically more relevant MCF7 and T47D breast cancer cells yielded similar FRET alterations upon addition of OH-tamoxifen and ICI-182,780. Since U2OS cells are more easily transfected, and since we wanted to study initial conformational changes in YFP-ER-CFP in cells devoid of endogenous ER, U2OS cells were used in further FRET studies.
Since ERα forms homodimers, the FRET changes observed could result from inter-or intramolecular energy transfer between CFP and YFP. To investigate this, we examined the FRET changes in U2OS cells that were transfected with either YFP-ER or ER-CFP alone or with equal amounts of both constructs ( Figure 2E) . No detectable FRET changes occurred upon tamoxifen addition in cells with either YFP-ER or ER-CFP expression alone, nor in cells expressing both constructs. These findings indicated that ER inactivation by anti-estrogens (Figure 2 ) resulted in an intramolecular change in ERα that can be visualized by FRET.
Resistance to anti-estrogens measured by FRET
The FRET probe was used for assaying conditions that induce resistance to the anti-estrogens tamoxifen or ICI-182,780 ( Figure 3A) . Depicted is the maximal alteration in FRET ratio, as shown in Figure 2 . We tested various factors associated with ligand-independent transactivation of ER, including SRC-1 (steroid receptor cofactor-1) (7), cyclin D1 (8) , and cAMP (4). As indicated in Figure 3A , membrane-permeable 8-Br-cAMP (33) prevented tamoxifen-associated FRET changes in YFP-ER-CFP transfected U2OS cells, whereas 8-Br-cAMP in combination with cyclin D1 and SRC-1 was required to overcome the ICI-182,780-induced FRET change. Without 8-Br-cAMP, overexpression of cyclin D1 and SRC-1, either alone or in combination, was not sufficient to overcome the tamoxifen or ICI-182,780-induced FRET change. ERE-dependent luciferase assays in U2OS cells were used to confirm that the changes in FRET were associated with inhibition of ER and subsequent reduction of ER transactivation, whereas resistance to anti-estrogens was associated with no alteration in FRET and with ER transactivation in the presence of anti-estrogens ( Figure 3B ). 
Cancer Cell
Chapter 9 | Tamoxifen resistance Administration of 8-Br-cAMP resulted in a 5.5-fold increase of the basal activity of the reporter construct under CTS conditions alone ( Figure 3B ) that is not accompanied by a FRET change. Only anti-estrogens induce a conformational change that results in a FRET alteration.
Next, we applied FRET to investigate the mechanism of resistance toward anti-estrogens induced by 8-Br-cAMP. This compound overcomes the tamoxifen-but not ICI-182,780-induced inactivation of ER, a situation often observed with tamoxifenresistant patients as well (20, 22) . cAMP is generated by adenylate cyclase activity, which can be stabilized by forskolin, and activates protein kinase A (PKA). When added to the YFP-ER-CFP transfected U2OS cells 15 min before anti-estrogen administration, forskolin prevented tamoxifen-, but not the ICI-182,780-induced, FRET change (Figures 4B and 4C) . Again, these findings were confirmed in ER-mediated transactivation experiments in the presence of 8Br-cAMP ( Figure 3B) . Surprisingly, addition of a 10-fold molar excess of ICI-182,780 after tamoxifen treatment did not result in a FRET change ( Figure 4B) . The estrogen binding site in ERα was apparently occupied by tamoxifen, thus preventing an ICI-182,780-induced FRET change. The reverse was also true: tamoxifen could not alter the ICI-induced conformational change as visualized by FRET ( Figure 4C) . Since ICI-182,780 substitution for tamoxifen was not observed in our experiments (up to 120 min), this indicated that anti-estrogens had a very low off-rate after ER binding. After PKA activation, tamoxifen failed to induce the inactive state of ERα, as measured by FRET (Figure 4B ), but instead induced ER-dependent transcription, as also visualized by the transactivation experiments ( Figure 3B) . PKA activation thus converted tamoxifen from an antagonist into an agonist.
There are two consensus PKA phosphorylation sites in ERα, one within the DNA binding domain (serine-236) and a second at the N-terminal boundary of the ligand binding E domain, near the hinge region (serine-305) (34) . Mutation of serine-236 to alanine had a partial effect (data not shown). Mutation of serine-305 to alanine, however, completely prevented the effect of forskolin on the tamoxifen induced, but not on the ICI-182,780-induced FRET change ( Figure 4D ). Serine 305 of ERα also appeared to be a bona fide target of PKA activity in an in vitro kinase assay ( Figure 4E) . The ERα ser→ala 236 mutant protein was efficiently phosphorylated, whereas the ser→ala 305 was not, indicating that not the ser-236 but rather the ser-305 site in ERα is the main target of PKA activity. We performed these kinase experiments in vitro to exclude activation/involvement of other kinases. PKA thus rendered ERα resistant to tamoxifen by phosphorylation of serine-305 in the hinge region. 
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Supplemental Tables S1 and S2 at http://www.cancercell.org/cgi/content/full/5/6/597/DC1. The expression profile of each tumor was analyzed using a pool of tumors as a reference. The association of expression of the different genes within the PKA pathway with tamoxifen sensitivity was evaluated by correlation of the average expression of each gene with the outcome of disease (32) . Only expression of the negative regulatory subunit of PKA, PKA-RIα, was found to be significantly reduced in tamoxifen-resistant breast tumors, whereas other components of the PKA pathway were not involved ( Table 1 and Supplemental Data). Among the 100 genes whose altered expression was associated with tamoxifen resistance, no gene involved in the MAP kinase pathway was found to be associated with tamoxifen resistance. Also, neither SRC-1 nor cyclin D1 was found to be associated with tamoxifen resistance, which is consistent with our FRET data that PKA activation alone (by cAMP) renders ERα resistant to tamoxifen. To substantiate the relevance of reduced expression of PKA-RIα, we downregulated PKA-RIα in the YFP-ER-CFP cells in our experimental system by RNAi (Figure 5A,  insert) . FRET analysis of U2OS cells cotransfected with the PKA-RIα RNAi construct showed no alteration in FRET upon tamoxifen treatment, whereas ICI-182,780 did induce a FRET change ( Figure  5A) . Again, addition of a ten-fold molar excess of ICI-182,780 after tamoxifen treatment did not yield a
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Chapter 9 | Tamoxifen resistance P-ATP, and the reactions were evaluated by autoradiography after gelectrophoresis and Western blotting using antibody against GFP as described in the Experimental Procedures. Total U2OS protein was used as control.
PKA-RIα and resistance to tamoxifen
We studied the relevance of PKA activation for tamoxifen resistance in 70 ER+ primary breast cancers that were isolated before tamoxifen treatment, of which 20 patients showed recurrence of the tumor. These primary tumors were consequently classified as tamoxifen-resistant. The remaining 50 patients showed no recurrence in the form of metastasis after an average follow-up period of 132 months, which classified these tumors as potentially tamoxifensensitive. However, the nonrecurrent group may have contained tamoxifen-resistant cases that did not show recurrence because of the absence of micrometastases. The clinical details of the patient groups and the microarray approach used in this study are given in FRET change, whereas addition of these compounds in the reverse order did show the regular ICI-182,780-associated FRET alteration. Tamoxifen resistance of ERα after PKA activation -through downregulation of PKA-RIα -was confirmed in traditional ERdependent transactivation assays that were performed in U2OS cells ( Figure 5B ) and in in vitro proliferation experiments, where ER-positive T47D breast cancer cells were used ( Figure 5C ). For FRET and ER-reporter assays, we used U2OS cells that are easily transfectable, but are not dependent on estrogen for their growth when transfected with ERα (35) . In contrast, growth of ER-positive T47D breast cancer cells is estrogen-dependent, and can be inhibited by antiestrogens. When T47D cells were transfected with PKA-RIα RNAi, however, they continued to proliferate in the presence of tamoxifen, but not with ICI 182,780. Activation of PKA by RNAi for PKA-RIα induced protein expression of a progesterone receptor related protein of 140 kDa that is normally induced by E2 only (data not shown). This suggests that tamoxifen-bound ERα can act as a transcriptional activator, like E2-bound ERα, after modification by PKA, as indicated by the transactivation reporter assays as well ( Figure 5B ). T47D cells transfected with an empty vector ceased to proliferate in the presence of these anti-estrogens ( Figure 5C ). Elevated PKA activity (by reduction of PKA-RIα) resulted in increased Table 2 . Colony density of T47D breast cancer cells transfected with PKA-RIα RNAi pSuper or with pSuper alone and cultured for three weeks under various hormonal conditions. After Coomassie blue staining, the density of the colonies presented in Figure 5C was measured as described by Brummelkamp et al. (29) , and is given in arbitrary units.
E2-driven proliferation as well, comparable to the increased ER transactivation measured by ERE luciferase activity under those conditions (Figure 3B ), as has also been reported previously (34) . Quantitation of colony densities of T47D cells with reduced levels of PKA-RIα as compared to controls indicated that growth in tamoxifen conditions exceeded that in conditions of ICI-182,780 or hormone ablation by approximately 2-fold, implying that both downregulation of PKA-RIα and tamoxifen were required for the increased cell growth ( Table 2) . Evidently, downregulation of PKA-RIα resulted in activation of the PKA pathway and induced selective tamoxifen resistance not only under experimental conditions, but also in breast cancer patients. Under these conditions, tamoxifen binds to ERα, but cannot induce the inhibitory conformation. Even more important, tamoxifen is now activating ER-controlled transcription and tumor cell growth.
Discussion
Here we show that PKA activation sufficed to induce tamoxifen resistance in breast cancer. In principle, this can be achieved by alteration of one or more steps within the PKA pathway (Figure 6 ). However, constitutive activation of PKA is difficult to achieve through G protein-coupled receptors or adenylate cyclase, because these receptors are desensitized after activation. Yet alteration can be achieved by overexpression of PKA or downregulation of the inhibitory subunit PKA-RIα, of which the latter occurred in most of the primary breast tumors that appear resistant to subsequent tamoxifen treatment (Table 1) . Obviously, we cannot exclude additional mechanisms for inducing tamoxifen resistance. Our experimental RNAi approach, however, showed that reduction of PKA-RIα alone was sufficient to induce tamoxifen resistance. Downregulation of PKA-RIα in breast tumor sections has already been associated with tamoxifen resistance (36) , but here we directly implicate this protein as a causative factor in this process and describe the mechanism of its action. By combining biophysical techniques (FRET) with microarray and RNAi technology, we have implicated the PKA pathway in tamoxifen resistance, not only in tissue culture cells, but also in breast cancer patients, and have identified ERα serine-305 as the critical target site. Interestingly, this site is located near the hinge region of ERα. Our FRET findings indicated that tamoxifen is able to bind to a PKA modified ERα (Figures 4B and 4C) . 
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Phosphorylation of serine-305 by PKA therefore appears to affect the stability of the conformation of ERα upon anti-estrogen binding rather than the binding properties of the receptor itself. FRET also revealed that tamoxifen induced resistance through a unique mechanism; PKA modified the ERα such that tamoxifen still bound to but was unable to convert the receptor into an inactive conformation. As a result, tamoxifen activated ER-mediated transcription and now acted as an agonist instead of an antagonist. This modification led to a specific tamoxifen-resistant proliferation, whereas sensitivity to ICI-182,780 remained unaltered. The stabilized conformation of ERα might lead to either enhanced recruitment of cofactors, such as SRC-1, or to reduced binding of corepressors, such as NCor. These factors are subject to modification of PKA themselves, which may contribute to recruitment/dissemination by/from ERα that is modified by PKA (37) . Resistance to ICI-182,780
was only achieved when additional factors, such as overexpression of SRC1 and cyclin D1, were involved (Figure 3) . In that case, it is likely that overexpression of cofactor SRC1 and cyclin D1 helped to stabilize the interaction between SRC1 and ERα, consolidating the PKA-induced conformational change in ERα even further. This resulted to an active conformation of ERα also in the presence of ICI-182,780, as measured by FRET. It is known that tamoxifen can act both as ER antagonist and agonist-antagonistic in breast tissue, while agonistic in a number of other tissues, such as osteoblasts (38) . For this reason, tamoxifen has beneficial effects on osteoporosis by stimulating ERα-dependent proliferation of osteoblasts. Why tamoxifen induces opposite effects in different tissues is unclear. Overexpression of SRC-1 has been claimed to be one factor (7) . However, our data showed that this did not suffice to convert the antagonistic effects of tamoxifen into an agonistic effect, unless PKA was activated as well. The activity of PKA may therefore be the critical factor. This is highly relevant for breast cancer patients, since tamoxifen may induce the opposite effect when PKA is activated, stimulating ERα-dependent tumor growth rather than inhibiting it. Indeed, this situation is encountered in the clinic in the "withdrawal response," where tamoxifenresistant breast tumor ceases to grow upon withdrawal of tamoxifen (39) . This counterintuitive effect of tamoxifen can be understood from our observations where tamoxifen is converted from an inhibitor into a growth stimulator when the estrogen receptor α is phosphorylated at position 305 by PKA. Patients who are potentially resistant to tamoxifen should be identified and treated with unequivocal ER antagonists such as ICI-182,780 (Fulvestrant). Indeed, 45% of the tamoxifen-resistant breast cancer patients respond favorably to treatment with Fulvestrant (21).
